Collagen-Targeted Therapeutics of Cathepsin Inhibitors

组织蛋白酶抑制剂的胶原蛋白靶向治疗

基本信息

  • 批准号:
    8771219
  • 负责人:
  • 金额:
    $ 21.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-01 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Numerous pathologic conditions (e.g. cancer, osteoporosis, arthritis, and fibrosis) are associated with excess collagen degradation mediated by distinct sets of proteases such as matrix metalloproteases (MMP), serine proteases, and cysteine proteases. Among them, cysteine cathepsins (cystein proteases) are considered one of the most important therapeutic targets as evidenced by various cathepsin knockout mice models. Although over 20 different types of cathepsin inhibitors have been developed, their on and/or off target cellular toxicity (lysosomotropic effect) has limited clinical use of these potenial drugs, and only a few are currently undergoing human trials. In light of recent findings that cathepsin's activity outside the cells are strongly associated with pathologic conditions, the ability to localize cathepsin inhibitor to extracellular spaces, in particular, to places where degradative activity is ongoing could lead to a breakthrough in clinical application of cathepsin and other protease inhibitors. This project will test the suitability of CMP as drug delivery agent for targeting degrading collagens in pathologic tissues, with particular focus on developing new synthetic conjugates of collagen mimetic peptide (CMP) and irreversible cathepsin K inhibitor. Overall objective of the proposed work is to explore the CMP mediated targeting capacity and therapeutic benefits of delivering irreversible cathepsin K (Cat-K) inhibitors to collagens undergoing degradation as related to developing anti-resorptive therapeutic agents for osteoporosis.
描述(由申请人提供):许多病理状况(例如癌症、骨质疏松症、关节炎和纤维化)与不同蛋白酶组(例如基质金属蛋白酶(MMP)、丝氨酸蛋白酶和半胱氨酸蛋白酶)介导的过度胶原降解相关。其中,半胱氨酸组织蛋白酶(半胱氨酸蛋白酶)被认为是最重要的治疗靶点之一,如各种组织蛋白酶敲除小鼠模型所证明的。尽管已经开发了超过20种不同类型的组织蛋白酶抑制剂,但它们的靶细胞毒性(亲溶酶体作用)限制了这些潜在药物的临床使用,并且目前只有少数正在进行人体试验。鉴于最近发现组织蛋白酶在细胞外的活性与病理状况密切相关,将组织蛋白酶抑制剂定位于细胞外空间,特别是降解活性正在进行的地方的能力可能导致组织蛋白酶和其他蛋白酶抑制剂的临床应用的突破。本项目将测试CMP作为靶向降解病理组织中胶原的药物递送剂的适用性,特别关注开发新的胶原模拟肽(CMP)和不可逆组织蛋白酶K抑制剂的合成缀合物。拟议工作的总体目标是探索CMP介导的靶向能力和将不可逆的组织蛋白酶K(Cat-K)抑制剂递送至正在降解的胶原蛋白的治疗益处,这与开发骨质疏松症的抗吸收治疗剂有关。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael S Yu其他文献

Michael S Yu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael S Yu', 18)}}的其他基金

Sustained Intravitreal Delivery of Ranibizumab Mediated by ECM Binding
ECM 结合介导的雷珠单抗玻璃体内持续递送
  • 批准号:
    9765322
  • 财政年份:
    2018
  • 资助金额:
    $ 21.26万
  • 项目类别:
Study and Application of Collagen Mimetic Peptide-Collagen Hybridization
胶原模拟肽-胶原杂交的研究及应用
  • 批准号:
    8664812
  • 财政年份:
    2011
  • 资助金额:
    $ 21.26万
  • 项目类别:
Study and Application of Collagen Mimetic Peptide-Collagen Hybridization
胶原模拟肽-胶原杂交的研究及应用
  • 批准号:
    8299014
  • 财政年份:
    2011
  • 资助金额:
    $ 21.26万
  • 项目类别:
Study and Application of Collagen Mimetic Peptide-Collagen Hybridization
胶原模拟肽-胶原杂交的研究及应用
  • 批准号:
    8031781
  • 财政年份:
    2011
  • 资助金额:
    $ 21.26万
  • 项目类别:
Study and Application of Collagen Mimetic Peptide-Collagen Hybridization
胶原模拟肽-胶原杂交的研究及应用
  • 批准号:
    8788304
  • 财政年份:
    2011
  • 资助金额:
    $ 21.26万
  • 项目类别:
Non-Covalent Modification of Collagen Scaffolds
胶原蛋白支架的非共价修饰
  • 批准号:
    6957114
  • 财政年份:
    2005
  • 资助金额:
    $ 21.26万
  • 项目类别:
Non-Covalent Modification of Collagen Scaffolds
胶原蛋白支架的非共价修饰
  • 批准号:
    7140253
  • 财政年份:
    2005
  • 资助金额:
    $ 21.26万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 21.26万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 21.26万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 21.26万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 21.26万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 21.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 21.26万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 21.26万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 21.26万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 21.26万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 21.26万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了